Avid Bioservices Inc (CDMO)

[entdoc]

thanks jess: amazinger and amazinger. "...Therefore, these results indicate that r84 may be more effective at
controlling tumor take and growth than bevacizumab independent
of dose in certain models. We propose that the appropriate
therapeutic antibody dose should be determined independently for
different tumor types to maximize therapeutic benefit with
minimal induction of toxicity [23–25]." Truly stuff worth reading. Great paper. congrats to all involved.